Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of “Moderate Buy” by Brokerages

Oculis Holding AG (NASDAQ:OCS) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $45.1429.

A number of research analysts recently weighed in on the stock. Needham & Company LLC raised their target price on shares of Oculis from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen lowered shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. HC Wainwright raised their price target on Oculis from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Stifel Nicolaus raised their price target on Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th.

Oculis Trading Up 0.2%

OCS stock opened at $30.29 on Friday. The firm has a fifty day moving average price of $27.36 and a 200 day moving average price of $24.57. Oculis has a fifty-two week low of $16.00 and a fifty-two week high of $34.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.96 and a current ratio of 5.18. The firm has a market cap of $1.76 billion, a PE ratio of -14.22 and a beta of 0.38.

Oculis (NASDAQ:OCS) last posted its earnings results on Monday, May 11th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. The business had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.25 million. Sell-side analysts anticipate that Oculis will post -2.18 earnings per share for the current fiscal year.

Institutional Trading of Oculis

Institutional investors have recently bought and sold shares of the stock. Aberdeen Group plc lifted its position in Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after buying an additional 493,827 shares during the last quarter. Gildi lifeyrissjodur bought a new stake in Oculis in the fourth quarter worth $50,250,000. Syquant Capital Sas bought a new stake in Oculis in the fourth quarter worth $3,849,000. China Universal Asset Management Co. Ltd. lifted its position in Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after buying an additional 1,000 shares during the last quarter. Finally, Himension Capital Singapore PTE. LTD. bought a new stake in Oculis in the first quarter worth $503,000. 22.30% of the stock is currently owned by institutional investors.

Oculis News Roundup

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and $47 price target, while also nudging up its near-term earnings estimates for Oculis, signaling continued confidence in the company’s clinical and financial outlook.
• Positive Sentiment: Lifesci Capital also raised several quarterly EPS forecasts for Oculis, reflecting a slightly improved earnings outlook from the analyst side.
• Positive Sentiment: At the 2026 Annual General Meeting, shareholders backed all proposals and Oculis added Gregory D. Perry, a veteran biotech CFO, to its board, which may be viewed as a governance and strategy-positive move. Article Title
• Positive Sentiment: Oculis also published transaction notifications tied to RSU vesting and equity awards for directors, which can indicate ongoing insider alignment with shareholders. Article Title
• Neutral Sentiment: The company’s latest reported quarterly results were mixed, with revenue slightly ahead of expectations but EPS missing estimates; however, these figures were already known and are less likely to be driving today’s move.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.